Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ELAINA: Kadcyla vs Lapatinib + Capecitabine in HER2+ Breast Cancer
NCT03084939Phase 3Completed
- Sponsor
- Roche
- Start
- Apr 2017
- Primary completion
- Nov 2018
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of trastuzumab emtansine in breast cancer (2 arms), sponsored by Roche. Primary endpoint: Progression-Free Survival. Started Apr 2017; status: completed.
02
Drugs
trastuzumab emtansine
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT03084939.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03084939.